Hussain M H, Pienta K J, Redman B G, Cummings G D, Flaherty L E
Section of Hematology/Oncology, VA Medical Center, Allen Park, Michigan 48101.
Cancer. 1994 Jul 1;74(1):100-3. doi: 10.1002/1097-0142(19940701)74:1<100::aid-cncr2820740118>3.0.co;2-k.
Hormone-refractory prostate cancer generally remains a chemotherapy-resistant tumor and therefore warrants the continued evaluation of promising agents.
Twenty-two eligible patients with hormone-refractory prostate cancer were treated with oral etoposide at a dosage of 50 mg/m2/day for 21 days in a 28-day cycle. Response was evaluated using standard solid tumor response criteria.
There were two partial responses of 6 and 14 months' duration, respectively. Two patients had disease stabilization, one for 6 months and one for 12 months. Median survival was 31 weeks, with an overall 1-year survival of 30%. Reversible alopecia and myelosuppression were the primary toxicities noted.
Single-agent oral etoposide has minimal activity in patients with hormone-refractory prostate cancer.
激素难治性前列腺癌通常仍是一种化疗耐药性肿瘤，因此有必要持续评估有前景的药物。
22例符合条件的激素难治性前列腺癌患者接受口服依托泊苷治疗，剂量为50mg/m²/天，持续21天，每28天为一个周期。使用标准实体瘤反应标准评估反应。
有2例部分缓解，持续时间分别为6个月和14个月。2例患者病情稳定，1例持续6个月，1例持续12个月。中位生存期为31周，1年总生存率为30%。主要观察到的毒性是可逆性脱发和骨髓抑制。
单药口服依托泊苷对激素难治性前列腺癌患者的活性极小。
